TRCT
VAXX

Tower Research Capital (TRC)’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

Tower Research Capital (TRC)’s Portfolio VAXX Stock Details VAXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,640
Closed -$9.08K – 6146
2024
Q1 		$9.08K Buy
12,640
+58
+0.5% +$42 ﹤0.01% 3902
2023
Q4 		$10.7K Buy
12,582
+2,573
+26% +$2.48K ﹤0.01% 4212
2023
Q3 		$13.7K Buy
10,009
+8,049
+411% +$17.4K ﹤0.01% 3762
2023
Q2 		$4.94K Sell
1,960
-13,002
-87% -$27.5K ﹤0.01% 4884
2023
Q1 		$34K Buy
14,962
+14,562
+3,641% +$36.9K ﹤0.01% 2878
2022
Q4 		$1K Buy
+400
New +$672 ﹤0.01% 5729
2022
Q3 		– Sell
-1,193
Closed -$1K – 6642
2022
Q2 		$1K Buy
+1,193
New +$4.51K ﹤0.01% 5906

Other funds holding VAXX

SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
RF
Robinswood Financial Kirkland, Washington $349M AUM 14.9% 1-Year Est. Return

Tower Research Capital (TRC)'s VAXX Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q2 2024, closing a stake of 12,640 shares — an estimated $9.08K sold.

Tower Research Capital (TRC) first reported a position in VAXX in Q2 2022 and held it in 7 quarters. The position peaked at $34K in Q1 2023. 8 funds tracked by Wall St. Rank hold VAXX as of Q2 2024.

  • Tower Research Capital (TRC) reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q2 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 12,640 Vaxxinity, Inc. Class A Common Stock shares in Q2 2024, an estimated $9.08K.
  • Tower Research Capital (TRC) first reported a position in Vaxxinity, Inc. Class A Common Stock in Q2 2022 and held it in 7 quarters.
  • Tower Research Capital (TRC)'s Vaxxinity, Inc. Class A Common Stock position peaked at $34K in Q1 2023.
  • 8 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.